Luke, J. J., Sweis, R. F., Hecht, J. R., Schneider, R., Stein, M. N., Golan, T., Yap, T. A., Khilnani, A., Huang, M., Zhao, R., Jemielita, T., & Patel, S. P. (2025). Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas. Clinical Cancer Research, 31(7), 1233–1242. https://doi.org/10.1158/1078-0432.ccr-24-2824